9,719 results match your criteria American journal of hematology[Journal]


Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.

Am J Hematol 2020 Jul 6. Epub 2020 Jul 6.

Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA.

FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML), and their presence confers adverse risk. FLT3-mutated (FLT3m) AML is a challenging leukemia to manage, particularly in older and unfit patients as well as patients with relapsed/refractory (r/r) disease. We retrospectively analyzed the outcomes of 50 FLT3m AML patients (17 treatment-naïve, 33 r/r) treated with venetoclax (VEN) and hypomethylating agents (HMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25929DOI Listing

Holistic Review for Hematology-Oncology Fellowship Applicants: A New Paradigm?

Am J Hematol 2020 Jul 6. Epub 2020 Jul 6.

Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25930DOI Listing

Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome.

Am J Hematol 2020 Jul 6. Epub 2020 Jul 6.

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25927DOI Listing

Efficacy and Safety of half-dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures.

Am J Hematol 2020 Jul 6. Epub 2020 Jul 6.

Department of Hematology, Rochester General Hospital, Rochester, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25928DOI Listing

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia.

Am J Hematol 2020 Jul 3. Epub 2020 Jul 3.

Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

The association of thrombocytosis with iron deficiency anemia (IDA) is well-recognized, but data describing the rate, predictors, and risk of thrombotic complications associated with IDA-related thrombocytosis are limited. We queried an institutional patient data repository containing comprehensive chart data for over 6 million patients to identify patients with IDA with and without thrombocytosis and thrombotic events over a 40-year time period (1979 to 2019). Demographics, hematological parameters, thrombosis history, and other medical history were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25925DOI Listing

Haploidentical Transplants for Patients with Relapse After the First Allograft.

Am J Hematol 2020 Jul 3. Epub 2020 Jul 3.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Relapse after allogeneic stem-cell transplantation (AHSCT) is associated with very poor outcomes. A second transplant offers the possibility of long-term disease control. We analyzed outcomes with haploidentical donors for second allograft at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25924DOI Listing

A six month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25920DOI Listing

Thrombotic Thrombocytopenic Purpura Masquerading as Preeclampsia With Severe Features at 13 Weeks' Gestation.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25914DOI Listing

Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Department of Medicine, Division of Hematology, University of Colorado School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25916DOI Listing

Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25913DOI Listing

Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Medical Department V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, INF 410, Heidelberg, Germany.

In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B-cell clone. We present 293 patients with immunohistochemically confirmed locAL. Lung (nodular pulmonary) with 63 patients was the most involved organ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25915DOI Listing

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Division of Hematology, Medical University of Graz, Graz, Austria.

Persistent measurable residual disease (MRD) is an increasingly important prognostic marker in acute myeloid leukemia (AML). Currently, MRD is determined by multi-parameter flow cytometry (MFC) or PCR-based methods detecting leukemia-specific fusion transcripts and mutations. However, while MFC is highly operator-dependent and difficult to standardize, PCR-based methods are only available for a minority of AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25918DOI Listing

Haploidentical Transplants for Patients with Graft Failure After the First Allograft.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25917DOI Listing

Gene therapies for transfusion dependent β-Thalassemia: current status and critical criteria for success.

Authors:
Sandeep Soni

Am J Hematol 2020 Jun 19. Epub 2020 Jun 19.

Division of Pediatric Stem Cell Transplant and RM, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA.

Thalassemia is one of the most prevalent monogenic diseases most frequently caused by quantitative defects in the production of β-globin leading to severe anemia. Technological advances in genome sequencing, stem cell selection, viral vector development, transduction and gene-editing strategies now allow for efficient ex-vivo genetic manipulation of human stem cells that can lead to correction leading to a meaningful clinical benefit in thalassemia patients. In this review, the status of the gene-therapy approaches available for transfusion dependent thalassemia are discussed, along with the critical criteria that affect efficacy and lessons that have been learned from the early phase trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25909DOI Listing

Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects.

Am J Hematol 2020 Jun 19. Epub 2020 Jun 19.

Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.

Phenotypic characterization of congenital platelet defects (CPDs) could help physicians recognize CPD subtypes and can inform on prognostic implications. We report the analyses of the bleeding phenotype and diagnostic characteristics of a large cohort of adult patients with a confirmed CPD. A total of 96 patients were analyzed and they were classified as Glanzmann thrombasthenia, Bernard-Soulier syndrome, dense granule deficiency, defects in the ADP or thromboxane A2 (TxA2) pathway, isolated thrombocytopenia or complex abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25910DOI Listing

The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.

Am J Hematol 2020 Jun 17. Epub 2020 Jun 17.

Georgia Cancer Center, Augusta, Georgia, USA.

We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥ 15% (n = 2), basophils ≥ 20% (n = 19), platelets < 100 × 109/L (n = 7), cytogenetic clonal evolution (n = 34), or more than 1 factor (n = 13). Thirty-three patients received imatinib; 42 received a second-generation tyrosine kinase inhibitor (2GTKI) (19 dasatinib and 23 nilotinib). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25907DOI Listing

Pediatric Hematology Normal Ranges Derived From Pediatric Primary Care Patients.

Am J Hematol 2020 Jun 12. Epub 2020 Jun 12.

Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25904DOI Listing

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation.

Am J Hematol 2020 Jun 12. Epub 2020 Jun 12.

Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, INSERM UMR 938 and Université Pierre et Marie Curie, Paris, France.

While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25905DOI Listing

Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).

Am J Hematol 2020 Jun 10. Epub 2020 Jun 10.

Centre for Haematology, St Mary's Hospital Campus, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25903DOI Listing

Carcinocythemia - cancer cell leukemia.

Am J Hematol 2020 Jun 10. Epub 2020 Jun 10.

Department of hemato-pathology at Lyndon B Johnson (LBJ) Hospital, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25902DOI Listing

Limitations of the particle immunofiltration assay test for diagnosis of heparin-induced thrombocytopenia.

Am J Hematol 2020 Jun 8. Epub 2020 Jun 8.

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25901DOI Listing

Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.

Am J Hematol 2020 Jun 8. Epub 2020 Jun 8.

Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

About half of patients with severe acute graft vs host disease (aGVHD) show resistance to treatment with first-line steroids. We enrolled 64 patients with grades III-IV SR-aGVHD after allogeneic hematopoietic stem cell transplantation (allo-SCT), to assess the efficacy and safety of the combination therapy of ruxolitinib and etanercept. The overall response rate was 87. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25898DOI Listing

Genetic screens reveal CCDC115 as a modulator of erythroid iron and heme trafficking.

Am J Hematol 2020 Jun 8. Epub 2020 Jun 8.

Department of Physiological Sceinces, University of Florida, Gainesville, Florida.

Transferrin-bound iron (TBI), the physiological circulating iron form, is acquired by cells through the transferrin receptor (TfR1) by endocytosis. In erythroid cells, most of the acquired iron is incorporated into heme in the mitochondria. Cellular trafficking of heme is indispensable for erythropoiesis and many other essential biological processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25899DOI Listing

Paraneoplastic pityriasis rubra pilaris heralding onset of new hematologic malignancy.

Am J Hematol 2020 Jun 5. Epub 2020 Jun 5.

Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25897DOI Listing

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

Am J Hematol 2020 Jun 5. Epub 2020 Jun 5.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25896DOI Listing
June 2020
3.798 Impact Factor

Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium.

Am J Hematol 2020 May 25. Epub 2020 May 25.

University of California San Francisco Benioff Children's Hospital Oakland, Oakland, California.

Understanding patient experiences, quality of life, and treatment needs in individuals with sickle cell disease (SCD) is essential in promoting health and well-being. We used measures from the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me), Patient Reported Outcomes Measurement Information System (PROMIS), and Quality of Life in Neurological Disorders (NeuroQol) to evaluate pain impact, sleep impact, social functioning, depressive symptoms, tiredness, and cognitive function (collectively, patient reported outcomes [PROs]) and to identify associated demographic and clinical characteristics. Participants (n = 2201) between 18 and 45 years were recruited through the eight Sickle Cell Disease Implementation Consortium (SCDIC) sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25880DOI Listing

Impact of detectable measurable residual disease on umbilical cord blood transplantation.

Am J Hematol 2020 May 25. Epub 2020 May 25.

EBMT Paris Study Office/CEREST-TC, Paris, France.

The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. Inclusion criteria included adult patients with acute myeloid (AML) or acute lymphoblastic leukemia (ALL), CBT as first allo-HCT in first or second complete remission (CR) at transplantation, and known MRD status at the time of CBT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25879DOI Listing

Risk-based, Response-adapted Therapy for Early-stage Extranodal Nasal-type NK/T-cell Lymphoma in the Modern Chemotherapy Era: A China Lymphoma Collaborative Group (CLCG) Study.

Am J Hematol 2020 May 25. Epub 2020 May 25.

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.

We aimed to determine the survival benefits of chemotherapy (CT) additional to radiotherapy (RT) in different risk groups of patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL) and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new-regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT+CT), or CT followed by RT (CT+RT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25878DOI Listing
May 2020
3.798 Impact Factor

Immune thrombocytopenia due to COVID-19 during pregnancy.

Am J Hematol 2020 May 23. Epub 2020 May 23.

Department of Clinical Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25877DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283860PMC

Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.

Am J Hematol 2020 May 21. Epub 2020 May 21.

Global Medical Affairs, Rare Hematology, Sanofi Genzyme, Cambridge, Massachusetts, USA.

Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6-metabolizer phenotypes (90% of patients). We report real-world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Registry (NCT00358943). As of January 2019, baseline and 2-year data (±1 year) were available for 231 eliglustat-treated GD1 patients: 19 treatment-naïve (zero splenectomized) and 212 ERT patients who switched to eliglustat (36 splenectomized). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25875DOI Listing

Disrupt, innovate, and transform in the era of COVID-19.

Authors:
John Nosta

Am J Hematol 2020 May 19. Epub 2020 May 19.

NostaLab, Mendham, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25866DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276889PMC

Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: A multi-center study.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Department of Medicine, Division of Hematology/Oncology, Mary M. Gooley Hemophilia Center, Rochester, New York, USA.

Increased awareness of von Willebrand Disease (VWD) has led to more frequent diagnostic laboratory testing, which insurers often dictate be performed at a facility with off-site laboratory processing, instead of a coagulation facility with onsite processing. Off-site processing is more prone to preanalytical variables causing falsely low levels of von Willebrand Factor (VWF) due to the additional transport required. Our aim was to determine the percentage of discordance between off-site and onsite specimen processing for VWD in this multicenter, retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25869DOI Listing

Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world outcome.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Division of Hematology, Blood & Marrow Transplantation, University of Kentucky Medical Center, Markey Cancer Center, Lexington, Kentucky.

Mixed phenotype acute leukemia (MPAL) is thought to have poor outcome, and presence of the Philadelphia chromosome (Ph+) has been considered to be an adverse prognostic marker. However, most of these reports were in the pre-tyrosine kinase inhibitors (TKIs) era. Recent limited reports indicate improved outcomes for MPAL with the addition of TKIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25873DOI Listing

ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

The optimal first-line treatment for advanced-stage Hodgkin's lymphoma (HL) is still a matter of debate. While ABVD is less toxic and as effective as other, more intensive chemotherapy regimens, escalated BEACOPP (BEACOPPesc) is superior to ABVD for initial disease control and prolonged time-to-relapse. However, this advantage is associated with higher rate of early and late toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25871DOI Listing
May 2020
3.798 Impact Factor

"ITP" is not always immune thrombocytopenia.

Am J Hematol 2020 May 17. Epub 2020 May 17.

Centre for Haematology, St Mary's Hospital Campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25872DOI Listing

The emergence of methemoglobinemia amidst the COVID-19 pandemic.

Am J Hematol 2020 May 15. Epub 2020 May 15.

Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25868DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276830PMC